Eli Lilly CDR (CAD Hedged)
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of [14C]-LY3866288 in Healthy Participants
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 15
- Registration Number
- NCT06644378
- Locations
- πΊπΈ
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 240
- Registration Number
- NCT06643728
- Locations
- πΊπΈ
Pinnacle Research Group, LLC, Anniston, Alabama, United States
πΊπΈGreat Lakes Clinical Trials - Ravenswood, Chicago, Illinois, United States
πΊπΈSKY Integrative Medical Center/SKYCRNG, Ridgeland, Mississippi, United States
A Study of LY3866288 in Healthy Participants
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 15
- Registration Number
- NCT06641037
- Locations
- πΊπΈ
Fortrea Clinical Research Unit, Dallas, Texas, United States
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 130
- Registration Number
- NCT06635057
- Locations
- πΈπ¦
King Fahad Armed Forces, Jeddah, Al Andalus, Saudi Arabia
πΈπ¦Saudi Airlines Medical services, Jeddah, AlKhalidiyyah, Saudi Arabia
πΈπ¦Dr Sulaiman Al Habib Medical Group-Olaya, Riyadh, Alolaya, Saudi Arabia
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
- Conditions
- Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal CancerAdvanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 750
- Registration Number
- NCT06607185
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈMayo Clinic, Phoenix, Arizona, United States
πΊπΈCity of Hope, Duarte, California, United States
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 230
- Registration Number
- NCT06606106
- Locations
- πΊπΈ
Collaborative Neuroscience Research, LLC, Los Alamitos, California, United States
πΊπΈFortrea Clinical Research Unit, Dallas, Texas, United States
πΊπΈClinical Pharmacology of Miami, Miami, Florida, United States
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
- Conditions
- Psoriatic ArthritisObesity
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 250
- Registration Number
- NCT06588296
- Locations
- πΊπΈ
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, Avondale, Arizona, United States
πΊπΈAARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler, Chandler, Arizona, United States
πΊπΈAARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff, Flagstaff, Arizona, United States
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 250
- Registration Number
- NCT06588283
- Locations
- πΊπΈ
Total Skin & Beauty Dermatology Center, PC DBA Total Dermatology, Birmingham, Alabama, United States
πΊπΈMedical Dermatology Specialists, Phoenix, Arizona, United States
πΊπΈScottsdale Clinical Trials, Scottsdale, Arizona, United States
Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 8
- Registration Number
- NCT06598631
- Locations
- π¦πΊ
Renal Research - Gosford, Gosford, New South Wales, Australia
π¨π³Taian City Central Hospital, Taian, Shandong, China
πΊπΈEndocrine Associates, Houston, Texas, United States
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 350
- Registration Number
- NCT06603571
- Locations
- πΊπΈ
NorCal Medical Research, Inc, Greenbrae, California, United States
πΊπΈVelocity Clinical Research, Huntington Park, Huntington Park, California, United States
πΊπΈPeninsula Research Associates, Rolling Hills Estates, California, United States